Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8650452 | Physiology & Behavior | 2018 | 31 Pages |
Abstract
Our data demonstrate that the GLP-1/GLP-2 co-agonists have effects on gut morphometry, showing a marked increase in intestinal volume and mucosal surface area. Furthermore, effects on glucose tolerance and long-term glycemic control are evident. Effects on body weight and gastric emptying are also observed depending on the pharmacokinetic properties of the molecule. We suggest that this novel co-agonistic approach could exemplify a novel concept for treatment of T2DM or SBS.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Physiology
Authors
Pernille Wismann, Søren L. Pedersen, Gitte Hansen, Karin Mannerstedt, Philip J. Pedersen, Palle B. Jeppesen, Niels Vrang, Keld Fosgerau, Jacob Jelsing,